Hormone therapy postmenopause “benefits are more likely to outweigh risks if initiated for symptomatic women before the age of 60 years or within 10 years after menopause”.1
Umbrella
What may the Hormone Therapy Postmenopause Umbrella include?
Depending on the Source (DotS) this Umbrella may include:
- Hormone Replacement Therapy (HRT) After Menopause
- Hormone Therapy (HT) After Menopause
- Menopausal Hormone Therapy (MHT) After Menopause
- Postmenopausal/Postmenopause Hormone Replacement Therapy (HRT)/Hormone Therapy (HT)
Revised Global Consensus Statement
What is one of the points of consensus about menopausal hormone therapy (MHT) and postmenopause?
One of the points of consensus in the Revised Global Consensus Statement on Menopausal Hormone Therapy: Section A: Benefit/Risk Profile of MHT – endorsed by seven menopause-related organizations – published online 20 June 2016, is:
- “MHT, including tibolone and the combination of conjugated equine estrogens and bazedoxifene (CE/BZA), is the most effective treatment for vasomotor symptoms (VMS) associated with menopause at any age, but benefits are more likely to outweigh risks if initiated for symptomatic women before the age of 60 years or within 10 years after menopause”.2
What are vasomotor symptoms?
The International Menopause Society (IMS) explain:
“Hot flushes and night sweats are also referred to as Vasomotor Symptoms (VMS)”.3
Type and Timing of Menopausal Hormone Therapy and… Meta-Analysis
What has feedback included about Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta-Analysis of the Worldwide Epidemiological Evidence, published in the Lancet on 29 August 2019?
On page one in The International Menopause Society Comment on: “Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta-Analysis of the Worldwide Epidemiological Experience” the IMS elaborate on:
- Much of the information regarding breast cancer risk and MHT reported in this paper is not new…
- It is important to note that, because of when the data included in this report was collected, most of the MHT regimes were different from those used today
- This paper provides an important public health message about obesity and breast cancer risk…”.4
What do the IMS recommend?
On page two in The International Menopause Society Comment on: “Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta-Analysis of the Worldwide Epidemiological Experience” the IMS explain:
Women enter menopause across a range of ages, with diverse symptoms and health risk profiles. The International Menopause Society advocates the comprehensive assessment of women, including attention to modifying risk factors for chronic disease such as being overweight or obese, the importance of which have been highlighted in this Lancet paper. The benefits and risks of MHT differ according to the timing of menopause such that individualisation of therapy is essential. As prescribing practices have changed significantly over the last decade, further research is needed to determine the impact of currently recommended regimens”.5
In Menopause Experts Dismiss Some Breast Cancer Claims In New Report the (Australian) Jean Hailes for Women’s Health elaborate on:
Where may I find Links related to Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta Analysis of the Worldwide Epidemiological Evidence, published in the Lancet on 29 August 2019?
Your Country may have Links similar to:
Links
This Links List to third party websites is neither comprehensive nor exhaustive. Inclusion on this Links List does not imply endorsement or recommendation. Non-inclusion on this Links List does not imply non-endorsement or non-recommendation. Third party websites are not under the control of Meno Martha International Menopause Directory. Third party websites may contain explicit medical images and/or sexual references. Please read Meno Martha International Menopause Directory’s Links Policy before proceeding to a Link. Please contact Webmaster if you experience a problem with a Link.- BMJ Editorial: HRT and Breast Cancer Risk: We Must Prevent Another Setback In Women’s Health [14 October 2019] [British Medical Journal]
- BMS Response To Lancet Paper on the Link Between Different Forms of HRT and Breast Cancer Incidence [30 August 2019]
- BMS Response To MHRA Recommendations [09 September 2019]
- Experts Debate New Analysis Concerning Breast Cancer Risk With Menopausal HT [06 September 2019]
- Experts Rip Into HRT-Cancer Study: From the Medical Republic – 9 September 2019
- Joint RCOG & BMS Statement In Response To the Lancet Study on HRT Use and Breast Cancer Risk [30 August 2019]
- MHT and Breast Cancer Risk
- Making Sense of Menopausal Hormone Therapy Means Understanding the Benefits As Well As the Risks [18 November 2019
- Menopausal Hormone Therapy Regimens Have Opposite Lasting Effects on Breast Cancer Incidence [13 December 2019]
- Menopause Experts Dismiss Some Breast Cancer Claims In New Report [30 August 2019]
- Menopause Matters [September 2019]
- Menopause: Diagnosis and Management – Information for the Public: Benefits and Risks of HRT – Breast Cancer [05 December 2019] [NICE Guideline]
- Resources / Podcasts: Menopause and Hormone Replacement Therapy (HRT) [21 October 2019]
- Resources / Webinar: The Breast Cancer and MHT Controversy – An Expert Panel Separates Fact From Fiction [15 November 2019]
- Response From MHRA/FOI [25 October 2019]
- Risks and Benefits of MHT/HRT [May 2019]
- Study Suggests HRT Carries Higher Risk of Breast Cancer Than Thought [03 September 2019]
- The International Menopause Society Comment on: “Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta-Analysis of the Worldwide Epidemiological Experience” [29 August 2019]
- Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta Analysis of the Worldwide Epidemiological Evidence [29 August 2019]
- We Don’t Know Menopausal Hormone Therapy Causes Breast Cancer, But the Evidence Continues To Suggest A Link [03 September 2019]
- Women’s Wellness: Does Menopausal Hormone Therapy Increase Risk of Breast Cancer? [30 August 2019]
Postmenopausal Bone Health
What are some points of consensus about MHT and postmenopausal bone health?
Some points of consensus in the Revised Global Consensus Statement on Menopausal Hormone Therapy: Section A: Benefit/Risk Profile of MHT are:
- “MHT, including tibolone and CE/BZA, is effective in the prevention of bone loss in postmenopausal women
- MHT has been shown to significantly lower the risk of hip, vertebral and other osteoporosis-related fractures in postmenopausal women
- MHT, including tibolone, can be initiated in postmenopausal women at risk of fracture or osteoporosis before the age of 60 years or within 10 years after menopause”.7
What is CE/BZA?
CE/BZA can be an abbreviation for Conjugated Equine Estrogens/Bazedoxifene.
Over Age 60
If I am postmenopausal and over aged 60 years, do I need to stop hormone therapy (HT)?
On page one in the NAMS 2017 Position Statement Updates Guidelines for Hormone Therapy Use the North American Menopause Society note:
- “For women who initiate HT more than 10 or 20 years from menopause onset or when aged 60 years or older, the benefit-risk ratio appears less favorable than for younger women because of greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia
- Hormone therapy does not need to be routinely discontinued in women aged older than 60 or 65 years and can be considered for continuation beyond age 65 years for persistent hot flashes, quality-of-life issues, or prevention of osteoporosis after appropriate evaluation and counseling of benefits and risks”.8
Health Care Provider
What if I am postmenopausal and choose to use HT?
If you are postmenopausal and choose to use HT, it may be in your best interest to also choose to talk to your health care provider about this.
One of the points of consensus in the Revised Global Consensus Statement on Menopausal Hormone Therapy: Section B: General Principles Governing the Use of MHT is:
- “The option of MHT is an individual decision in terms of quality of life and health priorities as well as personal risk factors such as age, time since menopause and the risk of VTE, stroke, ischemic heart disease and breast cancer. MHT should not be recommended without a clear indication for its use”.9
Health Topics A-Z
Where may I find Health Topics related to Hormone Therapy Postmenopause?
In Health Topics A-Z you may find:
Health Topics A-Z
- Hormone Therapy
- Hormone Therapy 2016 Revised Global Consensus Statement
- Hormone Therapy 2017 Update for Chronic Conditions
- Hormone Therapy and Heart Disease and Stroke Prevention
- Hormone Therapy and Menopause Symptoms
- Hormone Therapy and SERMs
- Hormone Therapy Alternatives
- Hormone Therapy Benefits and Risks
- Hormone Therapy Risks
- Postmenopause
Links
Where may I find Links related to Hormone Therapy Postmenopause?
Your Country may have Links similar to:
Links
This Links List to third party websites is neither comprehensive nor exhaustive. Inclusion on this Links List does not imply endorsement or recommendation. Non-inclusion on this Links List does not imply non-endorsement or non-recommendation. Third party websites are not under the control of Meno Martha International Menopause Directory. Third party websites may contain explicit medical images and/or sexual references. Please read Meno Martha International Menopause Directory’s Links Policy before proceeding to a Link. Please contact Webmaster if you experience a problem with a Link.- 9 Myths and Misunderstandings About Menopausal Hormone Therapy (MHT): 6. Myth – Complementary Medicines and Therapies Are As Effective As MHT and Safer
- 9 Myths and Misunderstandings About Menopausal Hormone Therapy (MHT): 7. Myth – Compounded Bioidentical Hormone Therapy Is Safer Than Conventional MHT
- Bioidentical Hormone Therapy
- Bioidentical Hormones Explained – A British Menopause Society Video
- Bioidentical Hormones: Are They Safer?
- ClinicalTrials.gov: Postmenopause Hormone Replacement Therapy
- ClinicalTrials.gov: Postmenopause Hormone Therapy
- ClinicalTrials.gov: Postmenopause Menopausal Hormone Therapy
- Cognitive Behaviour Therapy (CBT) for Menopausal Symptoms
- Combined Menopausal Hormone Therapy (MHT)
- Complementary Medicine Options for Menopausal Symptoms
- Complementary and Alternative Therapies Explained – A British Menopause Society Video
- Coronary Heart Disease (CHD) Explained – A British Menopause Society Video
- Deciding About Hormone Therapy
- Deciding About Hormone Therapy Use
- Decidir Sobre La Hormonoterapia
- Does Hormone Replacement Therapy Increase Cancer Risk?
- Early Menopause: Experiences and Perspectives of Women and Health Practitioners
- Early Menopause: Experiences and Perspectives of Women and Health Practitioners – Women’s Profiles
- Fact Sheets and Downloads: Additional Downloadable Resources – Vaginal Estrogen Therapy
- HRT
- HRT and Alternatives
- HRT and Breast Cancer: Overall Risks and Benefits Explained – A British Menopause Society Video
- HRT and the Risk of Breast Cancer Explained – A British Menopause Society Video
- Health After Menopause
- Hormone Help Desk: ET, EPT, and More
- Hormone Replacement Therapy
- Hormone Replacement Therapy (HRT)
- Hormone Replacement Therapy (HRT) Explained – A British Menopause Society Video
- Hormone Therapy In Postmenopausal Women: Primary Prevention of Chronic Conditions
- Hormone Therapy: Is It Right for You?
- Hot Flash Relief Without Hormones
- Hot Flashes: Manage Without Medication?
- Index To Drug-Specific Information [United States]
- Information About Menopause [Multiply Languages] [Videos]
- International Menopause Society Statement – Use of Postmenopausal Hormone Therapy and Risk of Alzheimer’s Disease In Finland: Nationwide Case-Control Study
- Is It Too Late To Start HRT At 60? – Ask Dr Jean
- Lifestyle and Behaviour Changes for Menopausal Symptoms
- Lifestyle and Behavioural Modifications for Menopausal Symptoms
- Maintaining Your Weight and Health During and After Menopause
- Making Choices At Menopause
- Managing Menopause: Don’t Let Symptoms of Menopause Reduce Your Quality of Life
- Mayo Clinic Minute: What Is Heart Disease?
- Menopause
- Menopause
- Menopause
- Menopause Explained – A British Menopause Society Video
- Menopause FAQs: Hormone Therapy for Menopause Symptoms
- Menopause FAQs: Hot Flashes
- Menopause FAQs: Your Health After Menopause
- Menopause Hormone Therapy and Your Heart
- Menopause Hormone Therapy: Who Shouldn’t Take It?
- Menopause Management: Menopausal Hormone Therapy (MHT)
- Menopause Symptoms and Relief
- Menopause Treatment
- Menopause and Women’s Health In Later Life
- Menopause and Your Health
- Menopause – Complementary Therapies [Multiply Languages] [Video]
- Menopause – How Will It Affect My Health [Multiply Languages] [Video]
- Menopause – Is Menopausal Hormone Therapy (HRT) Safe? [Multiply Languages] [Video]
- Menopause – Non-Hormonal Treatment Options [Multiply Languages] [Video]
- Menopause – What Is Menopausal Hormone Therapy (HRT)? [Multiply Languages] [Video]
- Menopause: Diagnosis & Treatment
- Menopause: Diagnosis and Management – Information for the Public: Questions To Ask About Menopause [NICE Guideline]
- Menopause: Hormone Replacement Therapy (HRT) [Video Interview Stories]
- Menopause: Medicines To Help You
- Menopause: Menopause – Hormone Treatments
- Menopause: Non-HRT and Lifestyle Options [Video Interview Stories]
- Menopause: Non-Hormonal Treatment & Relief for Hot Flashes
- Menopause: Profiles – Postmenopausal [Video Interview Stories]
- NAMS 2017 Position Statement Updates Guidelines for Hormone Therapy Use
- NAMS Supports Judicious Use of Systemic Hormone Therapy for Women Aged 65 Years and Older
- National Center for Complementary and Integrative Health: Herbs At A Glance
- National Center for Complementary and Integrative Health: How Safe Is This Product or Practice?
- National Center for Complementary and Integrative Health: Menopausal Symptoms: In Depth
- Non-Hormonal Treatment Options for Menopausal Symptoms
- NonHormonal Treatments for Menopausal Symptoms
- Oestrogen Only Menopausal Hormone Therapy
- Practical Prescribing Explained – A British Menopause Society Video
- Recent Review Confirms Safety of Low Dose Vaginal Estrogen: July 2019
- SERMs – Their Role In Menopause Management
- The North American Menopause Society Statement on Continuing Use of Systemic Hormone Therapy After Age 65
- Tibolone As Menopausal Hormone Therapy
- Tipos de Hormonoterapia
- Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta-Analysis of the Worldwide Epidemiological Evidence
- Types of Hormone Therapy
- Urogenital Atrophy Explained – A British Menopause Society Video
- Urogenital Problems
- Vaginal Dryness
- Vaginal Dryness
- Video Series-2018 – Moisturizers, Lubricants, and Prasterone
- Video Series-2020 – Bone Health What You Need To Know
- Video Series-2020 – TSECs—A New Treatment for Hot Flashes and Night Sweats
- Video Series-2020 – What You Need To Know About Bioidentical Hormone Therapy
- What Is Menopausal Hormone Therapy (MHT) and Is It Safe?
- Women Can Breathe Sigh of Relief When Using Vaginal Estrogen To Treat Menopause Symptoms
- Women’s Wellness: Hot Flashes and Night Sweats Happen After Menopause [+ Video Courtesy: Mayo Clinic News Network
Women’s Wellness: Mindfulness May Ease Menopausal Symptoms
- Women’s Wellness: Painful Sex After Menopause
- Women’s Wellness: Treating Hot Flashes and Night Sweats Without Hormones [+ Video]
Sources
Where may I find the Sources quoted?
You may find the Sources quoted at:
Sources
- De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Section A: Benefit/Risk Profile of MHT. Climacteric, 2016;19:4:313 https://www.imsociety.org/manage/images/pdf/ba6379e868044bec13015ac2b84f2753.pdf Accessed: 30 November 2020
- De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Section A: Benefit/Risk Profile of MHT. Climacteric, 2016;19:4:313 https://www.imsociety.org/manage/images/pdf/ba6379e868044bec13015ac2b84f2753.pdf Accessed: 30 November 2020
- Hot Flushes and Night Sweats – Background Information: What Are Hot Flushes and Night Sweats? October 2011:1. International Menopause Society https://www.imsociety.org/downloads/world_menopause_day_2011/wmd_media_backgrounder.pdf Accessed: 30 November 2020
- The International Menopause Society Comment on: “Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta-Analysis of the Worldwide Epidemiological Experience”. 29 August 2019:1. International Menopause Society https://www.imsociety.org/manage/images/pdf/2b650ccd4a2e0c63806d82ed2984ed69.pdf Accessed: 30 November 2020
- The International Menopause Society Comment on: “Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta-Analysis of the Worldwide Epidemiological Experience”. 29 August 2019:2. International Menopause Society https://www.imsociety.org/manage/images/pdf/2b650ccd4a2e0c63806d82ed2984ed69.pdf Accessed: 30 November 2020
- Menopause Experts Dismiss Some Breast Cancer Claims In New Report. 30 August 2019. Jean Hailes for Women’s Health https://jeanhailes.org.au/news/menopause-experts-dismiss-breast-cancer-claims-of-new-report Accessed: 30 November 2020
- De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Section A: Benefit/Risk Profile of MHT. Climacteric, 2016;19:4:313 https://www.imsociety.org/manage/images/pdf/ba6379e868044bec13015ac2b84f2753.pdf Accessed: 30 November 2020
- NAMS 2017 Position Statement Updates Guidelines for Hormone Therapy Use. 20 June 2017:1. North American Menopause Society https://www.menopause.org/docs/default-source/default-document-library/ht-press-release-061917.pdf Accessed: 30 November 2020
- De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Section B: General Principles Governing the Use of MHT. Climacteric, 2016;19:4:314 https://www.imsociety.org/manage/images/pdf/ba6379e868044bec13015ac2b84f2753.pdf Accessed: 30 November 2020